# Continuation Protocol for Obstructive Sleep Apnea (OSA)

> **NCT06566820** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Apnimed** · enrollment: 1280 (estimated)

## Conditions studied

- OSA

## Interventions

- **DRUG:** Aroxybutynin and Atomoxetine

## Key facts

- **NCT ID:** NCT06566820
- **Lead sponsor:** Apnimed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-07-03
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 1280 (ESTIMATED)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06566820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06566820, "Continuation Protocol for Obstructive Sleep Apnea (OSA)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06566820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*